Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.

doi:10.1021/acs.jmedchem.7b00793

Paper

Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.

Published Aug 10, 2017 · Elisa Azzali, D. Machado, A. Kaushik

Journal of medicinal chemistry

Q1 SJR score

65

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Tuberculosis remains one of the deadliest infectious diseases in the world, and the increased number of multidrug-resistant and extremely drug-resistant strains is a significant reason for concern. This makes the discovery of novel antitubercular agents a cogent priority. We have previously addressed this need by reporting a series of substituted 2-aminothiazoles capable to inhibit the growth of actively replicating, nonreplicating persistent, and resistant Mycobacterium tuberculosis strains. Clues from the structure-activity relationships lining up the antitubercular activity were exploited for the rational design of improved analogues. Two compounds, namely N-phenyl-5-(2-(p-tolylamino)thiazol-4-yl)isoxazole-3-carboxamide 7a and N-(pyridin-2-yl)-5-(2-(p-tolylamino)thiazol-4-yl)isoxazole-3-carboxamide 8a, were found to show high inhibitory activity toward susceptible M. tuberculosis strains, with an MIC90 of 0.125-0.25 μg/mL (0.33-0.66 μM) and 0.06-0.125 μg/mL (0.16-0.32 μM), respectively. Moreover, they maintained good activity also toward resistant strains, and they were selective over other bacterial species and eukaryotic cells, metabolically stable, and apparently not susceptible to the action of efflux pumps.

In Vitro Study

Study Snapshot

Substituted N-phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides show high inhibitory activity against susceptible and resistant Mycobacterium tuberculosis strains, with potential as a new antit

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.

Sign up to use Study Snapshot

References

A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors.

Phenotypic screening identified new antitubercular CTP synthetase inhibitors, highlighting the potential of this approach for tuberculosis drug discovery.

Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis

Prolonged bedaquiline treatment is effective and well-tolerated in multidrug-resistant tuberculosis patients.

Accepting the Invitation to Open Innovation in Malaria Drug Discovery: Synthesis, Biological Evaluation, and Investigation on the Structure-Activity Relationships of Benzo[b]thiophene-2-carboxamides as Antimalarial Agents.

The "Malaria Box" chemotypes show potential as a new antimalarial treatment, with potential for multiple parasite species and life stages, and a focus on structural features for in vitro activity and toxicity.

Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases.

Multitarget agents, which simultaneously act as broad-spectrum antivirals and correctors of the F508del-CFTR folding defect, show potential for treating enterovirus infections and pulmonary diseases in cystic fibrosis patients.

New and Old Hot Drug Targets in Tuberculosis.

New and old antitubercular drug targets are crucial for combating drug-resistant M. tuberculosis, with phenotypic screens improving the discovery of new effective compounds.

Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.

New and repurposed drugs, host-directed therapies, and biomarkers show promise in improving tuberculosis treatment outcomes and reducing therapy duration.

Design, Syntheses, and Anti-TB Activity of 1,3-Benzothiazinone Azide and Click Chemistry Products Inspired by BTZ043.

BTZ-N3 shows promising anti-TB activity, with a different activation mode and reversible noncovalent inhibition of DprE1 compared to BTZ043 and its congener PBTZ169.

Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials

MOX and GAT-containing regimens show non-inferiority or slightly better efficacy in initial tuberculosis treatment compared to the standard regimen, but may not shorten treatment duration.

Citations

Access to Isoxazoles via Photo-oxygenation of Furan Tethered α-Azidoketones.

Photocatalyst-free visible light-enabled direct oxygenation of furan-tethered -azidoketones produces isoxazoles, which show potential as -glucosidase inhibitors with good activity compared to standard drugs.

Aminopyridines in the development of drug candidates against protozoan neglected tropical diseases.

Aminopyridines show potential as new anti-NTD drugs due to their intrinsic properties and potential for use against protozoan neglected tropical diseases like Trypanosoma cruzi, Trypanosoma brucei, and Leishmania spp.

Antioxidant and Antimicrobial Activities of Some New Synthesized Triazole, Thiazolone, and Thiazine Containing Fused Rings of Imidazopyridine

New synthesized triazole, thiazolone, and thiazine compounds with fused rings of imidazopyridine show promising antimicrobial and antioxidant activities.

New Triazole-Isoxazole Hybrids as Antibacterial Agents: Design, Synthesis, Characterization, In Vitro, and In Silico Studies

Novel triazole-isoxazole hybrids show stronger antibacterial activity against Escherichia coli ATCC 25922 and Pseudomonas aeruginosa pathogenic strains, with good oral bioavailability and favorable pharmacokinetic characteristics.

Preliminary structure−activity relationships analysis on N-(3,5-dichlorophenyl)-4,5-dihydronaphtho[1,2-d]thiazol-2-amine, a disruptor of mycobacterial energetics

This study aims to develop efflux inhibitors with balanced activity, tolerable toxicity, and drug-like physicochemical features to combat mycobacterial drug-resistance.

An Efficient Synthesis, Antimicrobial Evaluation and In Silico Studies of 1,2,3‐Triazolyl‐isoxazolyl‐ethanol Derivatives

1,2,3-triazolyl-isoxazolyl-ethanol derivatives show good antimicrobial activity against various bacteria and fungi, with some showing good activity against A. niger.